Published in final edited form as:

Cancer Chemother Pharmacol. 2010 April ; 65(5): 833–838. doi:10.1007/s00280-009-1088-4.

A Phase I Trial of SJG-136 (NSC#694501) in Advanced Solid Tumors

Yelena Y Janjigian¹, Woojin Lee², Mark G Kris¹, Vincent A Miller¹, Lee M Krug¹, Christopher G Azzoli¹, Emir Senturk¹, M.Wade Calcutt³, and Naiyer A Rizvi¹

¹Thoracic Oncology Service, Division of Solid Tumor Oncology, Departments of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY

²Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington, KY

³Mass Spectrometry Research Center and Department of Biochemistry, Vanderbilt University Medical Center, Nashville, TN

Introduction

Many antitumor therapies, including alkylating agents and antibiotics, target DNA. Recently, interest in small molecules that target precise DNA sequences has increased, due to their potential to alter the transcription of specific genes. Pyrrolobenzodiazepine dimers (PBD) are a family of antitumor antibiotics derived from *Streptomyces* species that act by forming DNA crosslinks, interfering with endonuclease-DNA interactions, and inhibiting RNA polymerase activity [1–3]. SJG-136 is pyrrolobenzodiazepine dimer with an optimized chemical structure at the C2/C2'-positions, rationally designed to produce more efficient and selective covalent interactions with guanine in the minor groove of DNA [3, 4]. The SJG-136 pyrrolobenzodiazepine dimer (MW 556) spans six DNA base pairs and forms sequence-specific intrastrand crosslinks at Pu-GATC-Py sites, in which the recognition sequence is the central GATC string.

Results of National Cancer Institute's (NCI's) in vitro 60 cell line screen indicate that SJG-136 has a multi log differential pattern of activity [5]. Antitumor activity has been demonstrated in human tumor xenografts (LOX and UACC-62 melanoma, OVCAR-3 and OVCAR-5 ovarian cancer, MDA-MB-435 breast cancer, SF-295 and C-6 glioma, and LS-174T colon cancer) [6]. In addition, SJG-136 was also active in mice bearing cisplatin-resistant ovarian cancer xenografts (CH1cisR) [7].

We report the results of a phase I trial of SJG-136 in patients with refractory solid tumors. The primary objective was to establish the maximum tolerated dose (MTD) for intravenous SJG-136 administered on Days 1, 8 and 15 of a 28-day cycle. Pharmacokinetic parameters of SJG-136 were determined following intravenous administration of SJG-136 on Days 1 and 15 to assess the dose-proportionality and the impact of repeated SJG-136 dosing on SJG-136 pharmacokinetics.

Patients and Methods

All patients had pathologically-confirmed unresectable or metastatic cancer with a measurable indicator lesion. Each was 18 years old and had a Karnofsky Performance Status 60%. Patients were required to have absolute neutrophil count (ANC) 1,500/ μ L, platelets 100,000/ μ L, serum creatinine 1.4mg/dl, total bilirubin 1.0mg/dl, AST and ALT <2X upper limit of normal. There were no exclusions based on the number or duration of prior therapies. Patients must have recovered from the acute toxicities of any prior therapy and not received chemotherapy, radiation therapy or other investigational anticancer drug for at least 4 weeks prior to study entry. The protocol was approved by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center (MSKCC).

Study Design

All patients who received at least one dose of SJG-136 were assessed for toxicity. Dose limiting toxicity (DLT) was defined as grade 4 neutropenia, febrile neutropenia (ANC<1,000/ μ L and temperature >38 °C), grade 4 thrombocytopenia; or any grade 3 treatment-related non-hematologic toxicity excluding nausea, vomiting, allergic reaction, and alopecia. Patients were assessed for toxicity according to National Cancer Institute Common Terminology Criteria of Adverse Events, version 3.0. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST).

Based on murine and canine studies, the recommended clinical starting dose of SJG-136 has been defined. Based on the dog as the most sensitive species with an MTD of 24 μ g/m²/day, the recommended clinical starting dose for a daily for 5 days schedule is 1/6 of the dog MTD, or 4 μ g/m²/day. As we were interested in evaluating a Day 1, 8, and 15 every 28-day schedule the starting dose chosen was 10 μ g/m²/day. The planned dose escalation increment was 100% until a DLT occurred or if two or more patients experienced grade 2 toxicity where after dose escalation would follow a modified Fibonacci scheme (dose increments of 50%, 40%, 33% and 25% for further dose escalations). Three patients were enrolled at each dose level starting at dose level 1. If no DLT was observed after 1 treatment cycle (4 weeks), 3 patients were enrolled at the next dose level. If 1 DLT was observed, the dose level was expanded to 6 patients. If 2 DLTs were observed at a dose level there were no further dose escalations as the MTD has been exceeded. The dose level below was considered the MTD providing a DLT was observed in less than 2 of 6 treated patients at that dose level.

Drug and Treatment

SJG-136 (NSC #694501) was distributed by the Pharmaceutical Management Branch/NCI in 10 μ g (1 mL) and 50 μ g (5 mL) sterile single-use vials at a concentration of 10 μ g/mL. Drug was administered over 20 minutes without corticosteroid or antihistamine premedication on Days 1, 8, and 15 of a 28-day cycle. All patients had a medical history, physical examination and laboratory work at baseline and before each dose of SJG-136. A complete blood count was performed weekly for the first and second cycle and then on Days 1, 8 and 15 of all subsequent cycles. A comprehensive metabolic panel (electrolytes, serum creatinine, liver function tests and calcium) was performed Days 8, 15 and 21 of cycle 1 and Days 1, 8, 15 and 21 of cycle 2 and days 1 and 15 of all subsequent cycles. Before administration of SJG-136, ANC 1,500/ μ L and platelets 100,000/ μ L were required. All non-hematologic toxicities had to recover to Grade 0–1 or baseline (except alopecia). Up to 4 weeks (1 cycle) of treatment delay was permitted to allow sufficient time for recovery. If dosing was held for more than 4 weeks as the result of toxicity, the patient was removed from study. Dose reductions by 1 or 2 dose levels were permitted for toxicities. Filgrastim was not used prophylactically. Patients continued treatment with SJG-136 until development of progressive disease or intolerance of treatment.

Pharmacokinetic (PK) analysis

PK studies of SJG-136 were performed on Days 1 and 15 of cycle 1. Serial blood samples were collected at 10, 20 min (end of infusion), 22, 25, 30, 50, 65, 80, 110, 140, 260 minutes following intravenous SJG-136 administration. The plasma samples were separated by centrifugation and stored at -80°C until analysis.

Determination of SJG-136 plasma concentration levels was performed using a recently validated liquid chromatography mass spectrometry analytical method [8]. Non compartmental PK parameters were obtained using the WinNonlin software package, version 4.1 (Pharsight Corp., Palo Alto, CA). The area under the concentration-time curve from time 0 to the last time point (260 min) (AUC_{last}) was calculated using the linear trapezoidal method. The remaining area under the curve from the last time point to infinity was calculated using the equation $\text{AUC}_{\text{last}-\infty} = C_{\text{last}}/K_{\text{el}}$, where C_{last} is the last measured plasma concentration and K_{el} is the slope of the concentration versus time plot during the log-linear terminal phase. Total clearance (CL) and volume of distribution at steady state (V_{ss}) were calculated as follows: $\text{CL} = \text{Dose}/\text{AUC}$; $V_{\text{ss}} = \text{Mean Residence Time (MRT)} \times \text{CL}$.

Results

Patients

Between 11/30/04 and 2/13/07, 21 patients were enrolled in this single-institution study. The pretreatment characteristics are summarized in Table 1. The majority of patients had lung cancer (42%) and melanoma (38%). Patients received a median of 2 prior chemotherapy regimens.

Adverse events

Adverse events were assessed in all 21 patients. Treatment was initiated at $10\text{ }\mu\text{g}/\text{m}^2/\text{day}$ with patients observed for 4 weeks before escalation to next dose level was allowed. The SJG-136 dose was escalated to $20\text{ }\mu\text{g}/\text{m}^2$, $40\text{ }\mu\text{g}/\text{m}^2$, $60\text{ }\mu\text{g}/\text{m}^2$ in consecutive patient cohorts.

A median of 1 cycle (range 1–8) was completed for all patients (Table 2). Doses were not reduced. Therapy was discontinued due to progression of disease in 18 of 21 patients (86%). Three of 21 patients (14%) discontinued treatment due to treatment-related toxicity.

Table 3 summarizes adverse events at all dose levels that were assessed by the investigator as related or possibly related to treatment with SJG-136. At the first dose level, three patients were treated with SJG-136 $10\text{ }\mu\text{g}/\text{m}^2/\text{day}$. Grade 2 toxicities that each occurred in one patient were nausea, leukopenia and neutropenia. Two patients experienced grade 1 transaminitis. Other grade 1 toxicities that occurred once, included hypoalbuminemia, dyspepsia, diarrhea, fatigue, pruritus, nail changes, and mucositis. One patient underwent dose escalation to $20\text{ }\mu\text{g}/\text{m}^2/\text{day}$ on cycle 8, day 8.

At the second dose level 3 patients were treated with SJG-136 $20\text{ }\mu\text{g}/\text{m}^2/\text{day}$. One patient experienced grade 3 transaminitis in the beginning of cycle 4 probably related to the investigational treatment. Because the grade 3 transaminitis did not occur during cycle 1, expansion of the patient cohort at the second dose level was not required. Grade 2 toxicities, occurring in one patient each, were: transaminitis and hypoalbuminemia. Grade 1 transaminitis, hypoalbuminemia, hyperbilirubinemia, alkaline phosphatase elevation, nausea, fatigue each occurred in one patient.

At the third dose level 3 patients were treated with SJG-136 $40\text{ }\mu\text{g}/\text{m}^2/\text{day}$. One patient experienced grade 2 fatigue. Two patients experience grade 1 fatigue and one patient

experience grade 1 neuropathy. No DLTs occurred at this dose; therefore, dose escalation was permitted.

After dose level 3 the protocol was amended to allow a more conservative dose escalation. As such subsequent patients were escalated with a standard dose escalation study design with a modified Fibonacci scheme (dose increments of 50%, 40%, 33% and 25% for further dose escalation). In addition, due to delayed liver toxicity reported by investigators elsewhere, the patients were observed for toxicity for 8 weeks prior to dose escalation.

Seven patients were treated at the fourth dose level (SJG-136 60 $\mu\text{g}/\text{m}^2/\text{day}$). Initially, three patients were enrolled. The first patient experienced grade 2 fatigue and grade 3 thrombocytopenia during cycle 1. Although grade 3 thrombocytopenia was not defined in the protocol as a DLT, it precluded this patient from receiving further SJG-136 treatment. She subsequently developed disease progression and was taken off study. The second patient experience grade 3 fatigue during cycle 1, therefore the dose level was expanded. The third patient experienced grade 2 diarrhea and grade 2 fatigue during cycle 1. During cycle 2 the patient experienced grade 2 hypoalbuminemia, grade 2 myalgias/thigh swelling and persistent grade 2 fatigue precluding further therapy. He subsequently developed progression of disease and was taken off the study. The fourth patient, experienced grade 3 fatigue during cycle 1. That patient had a fatal CNS hemorrhage in his tumor 4 days later unrelated to SJG-136 therapy. Grade 3 fatigue was attributed to CNS metastatic disease progression and therefore this patient was replaced. The fifth patient experienced dose limiting grade 3 fatigue upon completion of cycle 1 and was taken off study shortly thereafter due to disease progression. The sixth patient experienced grade 2 lower extremity edema, grade 2 fatigue and grade 2 hypoalbuminemia during cycle 1. The patient gained 10 pounds during cycle 1 of SJG-136 therapy. Initiation of cycle 2 was delayed by 3 weeks in this patient due to persistent grade 2 lower extremity edema and hypoalbuminemia. The patient received furosemide with improvement in his lower extremity edema to grade 1 and reinstitution of SJG-136 therapy. At the end of cycle 2 the patient experience grade 2 dyspnea. Computed tomography of the chest one week later revealed numerous patchy alveolo-interstitial nodules scattered throughout both lung fields, suggestive of pneumonitis. This was determined possibly related to the study drug and the patient was removed from the study. The seventh patient experienced grade 2 hand swelling and tenderness possibly related to SJG-136 infusion. She was subsequently taken off study for disease progression. The following grade 2 toxicities occurred once in the fourth dose level cohort: alkaline phosphatase elevation, fatigue, thrombocytopenia, mental status change.

Because 3 patients at the fourth dose level experienced dose-limiting toxicity, grade 3 fatigue, the MTD was exceeded and dose level 3 (SJG-136 40 $\mu\text{g}/\text{m}^2/\text{day}$) was expanded to include five additional patients. Based on preclinical data demonstrating activity in colon cancer, the cohort was further expanded to five instead of three patients to include 2 additional patients with colon cancer. One patient experienced grade 2 fatigue. Two patients experience grade 2 hypoalbuminemia. Grade 1 transaminitis and hypoalbuminemia occurred in three patients each. Grade 1 nausea occurred in two patients. Grade 1 mucositis, depression, vomiting, fatigue, limb edema and hyperbilirubinemia occurred in one patient each.

Antitumor activity

Thirteen patients were assessed for tumor response using RECIST criteria. No objective tumor responses were noted for any of the patients. One patient with metastatic melanoma achieved stable disease for 8 cycles. The patient was initially treated with SJG-136 10 $\mu\text{g}/\text{m}^2/\text{day}$ and underwent intra-patient dose escalation on day 8, cycle 8. She tolerated the

treatment well but was subsequently taken off the study after day 15, cycle 8 for progression of disease.

Pharmacokinetic data

PK data were obtained from 19 patients (Figure 1 and Table 4). The plasma concentrations of SJG-136 were above the assay detection limit at all the time points and at all dose levels tested. The pre-dose concentrations of SJG-136 on Day 15 were below the detection limit of our assay in all the patients, indicating that no significant accumulation of SJG-136 on Day 15. SJG-136 pharmacokinetics appears to be linear in the dose range tested (10 – 60 $\mu\text{g}/\text{m}^2/\text{day}$) based on the dose proportional increases in SJG-136 systemic exposure (i.e. AUC_{last} and C_{max}) (Figure 1B and Table 4). Other PK parameters such as clearance (CL) and volume of distribution at steady state (V_{ss}) did not show any statistically significant differences across different doses and between Days 1 and 15 (Table 4).

Discussion

SJG-136 targets precise DNA sequences and has shown activity in cisplatin-resistant tumor xenografts. Preclinical data showed the best activity in animal models using repeated SJG-136 dosing. The current study determined a MTD of SJG-136 given on Days 1, 8 and 15 of a 28-day cycle in patients with advanced solid tumors. Grade 3 toxicities of fatigue, thrombocytopenia and transaminitis were observed. When SJG-136 was given at a dose of 60 $\mu\text{g}/\text{m}^2/\text{day}$, the MTD was exceeded with dose-limiting fatigue occurring in 42% (3 of 7) of patients. Additionally, 14% (1 of 7) of patients experienced grade 3 thrombocytopenia during cycle 1. Delayed grade 3 transaminitis was seen 33% (1 of 3) patients at dose level 3 (SJG-136 20 $\mu\text{g}/\text{m}^2/\text{day}$), similar to the experience from published Phase I data. Although, edema, transaminitis and hypoalbuminemia were not determined to be DLTs in our study, these toxicities were frequently experienced by our patients. Grade 2 hypoalbuminemia and transaminitis were seen in 33% (1 of 3) patients at dose level 2. Grade 2 hypoalbuminemia and edema were seen in 25% (2 of 8) patients at dose level 3, 28% (2 of 7) patients at dose level 4. PK parameters of SJG-136 indicated dose-proportional increases in systemic exposure of SJG-136 with increasing doses of SJG-136.

Investigators at Vanderbilt-Ingram Cancer Center (Nashville, TN, USA) conducted a phase I study of SJG-136 in patients with refractory solid tumors [9]. SJG-136 was initially administered daily for 5 days every 21 days. Grade 3 DLT of edema, dyspnea, fatigue was observed in cycle one at 48 $\mu\text{g}/\text{m}^2/\text{day}$. Similar toxicity was observed in cycle 2 at 24 $\mu\text{g}/\text{m}^2/\text{day}$ study. Grade 4 delayed liver toxicity was also reported with this schedule. Investigators were unable to dose escalate, therefore the protocol was amended to shorten daily administration to 3 days with dexamethasone premedication and diuretic support to reduce the vascular leak syndrome manifestations. Fourteen patients were treated with SJG-136 administered intravenously daily for 3 days in a 21 day cycle at the initial dose level of 20 $\mu\text{g}/\text{m}^2/\text{day}$. Soft tissue edema, dyspnea and fatigue were the DLTs in one of the two patients enrolled at 35 $\mu\text{g}/\text{m}^2/\text{day}$ dose and transaminitis in the second patient. No significant myelosuppression was observed. The recommended phase II dose from this study was determined to be 30 $\mu\text{g}/\text{m}^2/\text{day}$ administered daily for 3 days in 21 days cycle. Pharmacokinetic (PK) analysis revealed dose-dependent increases in SJG-136 systemic exposure [9]. In another Phase I study of 16 refractory solid tumor patients, SJG-136 was administered at escalating doses (15–240 $\mu\text{g}/\text{m}^2/\text{day}$) intravenously once every 21 days. The major DLT were delayed onset vascular leak syndrome (peripheral edema, hypoalbuminemia, pleural effusions, and ascites) and liver toxicity. SJG-136 demonstrated biphasic clearance and linear PK across the dose range tested. The investigators determined the MTD for SJG-136 to be 45 $\mu\text{g}/\text{m}^2$, but a recommended phase II dose was not identified [10].

In summary, SJG-136 administered on Days 1, 8 and 15 of a 28-day cycle was associated with fatigue, thrombocytopenia and hypoalbuminemia and delayed transaminitis. Forty $\mu\text{g}/\text{m}^2/\text{day}$ was the maximum tolerated dose of SJG-136 administered at this dosing schedule. Although the increases in C_{max} and AUC values were dose-proportional at the SJG-136 levels examined (10–60 $\mu\text{g}/\text{m}^2/\text{day}$), a larger study would be necessary to further verify dose-linear pharmacokinetics of SJG-136. No objective tumor responses were noted. Alternative dosing strategies that include dexamethasone premedication and diuretic support are now being evaluated.

Acknowledgments

Supported by CTEP, NIH 5U01CA069856-15; NCI-sponsored trial # 6818

References

1. Puvvada MS, Hartley JA, Jenkins TC, et al. A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumor antibiotics based on the inhibition of restriction endonuclease BamHI. *Nucleic Acids Res.* 1993; 21(16):3671–3675. [PubMed: 8367284]
2. Puvvada MS, Forrow SA, Hartley JA, et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines. *Biochemistry.* 1997; 36(9): 2478–2484. [PubMed: 9054552]
3. Gregson SJ, Howard PW, Hartley JA, et al. Design, Synthesis, and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity. *Journal of Medicinal Chemistry.* 2001; 44(5):737–748. [PubMed: 11262084]
4. Thurston, DE. Advances in the study of pyrrolo[2,1-c] [1,4]-benzodiazepine (PBD) antitumor antibiotics, in *Molecular Aspects of Anticancer Drug-DNA Interactions*. Neidle, S.; Waring, MJ., editors. London: The Macmillan Press Ltd.; 1993. p. 64-88.
5. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. *J Natl Cancer Inst.* 1989; 81(14):1088–1092. [PubMed: 2738938]
6. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. *Cancer Res.* 2004; 64(18):6700–6706. [PubMed: 15374987]
7. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. *Cancer Res.* 2004; 64(18):6693–6699. [PubMed: 15374986]
8. Wade Calcutt M, Lee W, Puzanov I, et al. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. *J Mass Spectrom.* 2008; 43(1):42–52. [PubMed: 17683023]
9. Puzanov I, Lee W, Berlin JD, et al. Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily $\times$ 3 schedule. *J Clin Oncol (Meeting Abstracts).* 2008; 26(15_suppl):2504-.
10. Hochhauser D, Meyer T, Spanswick VJ, et al. Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2009; 15(6):2140–2147. [PubMed: 19276288]

Figure 1.

A: Average plasma concentration vs time profiles of SJG-136 following intravenous administration of SJG-136 at 10, 20, 40 and 60 µg/m² on Day 1 in cycle 1. B: Comparison of AUC_{last} and C_{max} obtained on Days 1 and 15 following intravenous SJG-136 administration at increasing doses.

Table 1

Patient Characteristics n = 21

Age (years)	
Median	65
Range	45–78
Sex	
Female	10 (47%)
Male	11 (52%)
Karnofsky Performance Status	
80%	18 (86%)
70%	3 (14%)
Primary site	
Lung	9 (42 %)
Melanoma	8 (38%)
Colon	2 (9%)
Bladder	1 (5%)
Ovarian	1 (5%)
Number of prior chemotherapy regimens	
Median	2
Range	0 –4
Prior Radiotherapy	3 (14%)

Table 2

SJG-136 Exposure

SJG 136 dose* ($\mu\text{g}/\text{m}^2/\text{day}$)	No. of patients treated	Median no. of cycles	DLT
10	3	7	0
20	3	1	0
40	8	2	0
60	7	1	3

* No dose reductions were done

Table 3

Treatment-related toxicities of SJG-136 (all doses)

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4
Bone Marrow				
Leukopenia	1	1	0	0
Neutropenia	0	1	0	0
Anemia	3	0	0	0
Thrombocytopenia	0	1	1	0
Cough	1	0	0	0
Depression	1	0	0	0
Dyspnea	0	1	0	0
Edema/Limb	1	3	0	0
Fatigue	1	4	3	0
Gastrointestinal				
Constipation	1	0	0	0
Diarrhea	2	1	0	0
Nausea	9	1	0	0
Vomiting	3	0	0	0
Hemorrhage, other	1	0	0	0
Hepatic				
Bilirubin elevation	2	0	0	0
ALT elevation	6	1	1	0
AST elevation	8	1	0	0
Alkaline phosphatase elevation	1	1	0	0
Hypoalbuminemia	12	6	0	0
Hypocalcemia	2	0	0	0
Hyponatremia	1	0	0	0
Mental Status Change	0	1	0	0
Mucositis	4	0	0	0
Neuropathy	2	0	0	0
Nail Changes	1	0	0	0
Pain (extremity)	0	1	0	0
Pruritus	1	0	0	0
Rash, desquamation	1	0	0	0

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4
Weight gain	1	0	0	0

Table 4

Pharmacokinetic parameters of SJG-136 following intravenous SJG-136 administration of 10, 20, 40 or 60 $\mu\text{g}/\text{m}^2/\text{day}$

		Dose level ($\mu\text{g}/\text{m}^2/\text{day}$)			
		10 (n=3)	20 (n=3)	40 (n=6)	60 (n=7)
C_{max} (ng/mL)	Day 1	2.3 (1.2)	3.7 (2.2)	10.1 (4.0)	17.7 (5.4)
	Day 15	2.3 (0.5)	6.2 (5.2)	11.6 (4.3)	17.6 (4.2)
AUC_{last} (ng·min/mL)	Day 1	83.1 (36.7)	156.5 (84.0)	443.8 (201.8)	773.8 (207.2)
	Day 15	81.0 (10.5)	211.7 (124.9)	484.9 (231.8)	698.4 (194.4)
AUC_{infinity} (ng·min/mL)	Day 1	88.5 (40.7)	166.0 (219.5)	459.6 (207.3)	809.4 (216.1)
	Day 15	87.4 (13.2)	219.5 (122.0)	504.4 (244.7)	727.2 (194.2)
CL (mL/min/m ²)	Day 1	134.5 (64.2)	160.0 (111.8)	100.2 (34.4)	80.6 (28.0)
	Day 15	116.6 (19.1)	118.4 (75.9)	102.6 (57.9)	87.9 (22.8)
V_{ss} (mL/m ²)	Day 1	8171 (4833)	12090 (10810)	5837 (3226)	4977 (1637)
	Day 15	7769 (749)	8761 (8604)	5736 (2759)	5525 (2320)